Trending Tickers: Philip Morris International (NYSE:PM), Itau Unibanco Holding SA (ADR) (NYSE:ITUB), Nuance Communications (NASDAQ:NUAN), BIND Therapeutics (NASDAQ:BIND), Merck (NYSE:MRK)

On Wednesday shares of Philip Morris International, Inc. (NYSE:PM) closed at $78.13. Company’s sales growth for last 5 years was 3.50% and EPS growth for next 5 years is recorded as 5.40%. Philip Morris International, Inc. (NYSE:PM) said that, it will host a live audio webcast, April 16, 2015, at 9:00 a.m. ET to discuss its 2015 first-quarter results, which will be issued at approximately 7:00 a.m. ET the same day.

Itau Unibanco Holding SA (ADR) (NYSE:ITUB) in last trading activity advanced 2.01% to close at $12.19. Company weekly performance is -0.25% while its quarterly performance stands at -2.64%. Itau Unibanco Holding SA (ADR) (NYSE:ITUB) is -32.14% away from its 52 week high. Itau Unibanco Holding SA (ADR) (NYSE:ITUB)‘s stock had its “neutral” rating reissued by analysts at Credit Suisse Group AG in a research report issued to clients and investors on Thursday.

On last trading day Nuance Communications, Inc. (NASDAQ:NUAN) advanced 0.70% to close at $14.31. Its volatility for the week is 0.93% while volatility for the month is 1.52%. NUAN’s sales growth for past 5 years was 15.10% and its EPS growth for past 5 years was -42.50%. Nuance Communications, Inc. (NASDAQ:NUAN) monthly performance is 3.17%. Nuance Communications, Inc. (NASDAQ:NUAN) announced that it will showcase its newest innovations for bringing clinical documentation to smart devices, smart watches and the Internet of Things at the 2015 Health Information Management Systems Society (HIMSS) Annual Conference. In conjunction with this year’s event, Nuance has announced PowerMic Mobile, which will be available in May 2015.

BIND Therapeutics, Inc. (NASDAQ:BIND) has 1.70% insider ownership while its institutional ownership stands at 39.70%. In last trading activity company’s stock closed at $8.02. On 9 April, BIND Therapeutics, Inc. announced that it has extended the terms of its global collaboration with Pfizer Inc. PFE to create Accurins (targeted and programmable therapeutics) that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline.

Merck & Co. Inc. (NYSE:MRK) in last trading activity advanced 1.19% to close at $58.45. Company weekly performance is 2.27% while its quarterly performance stands at -5.25%. Merck & Co. Inc. (NYSE:MRK) is -7.38% away from its 52 week high. On 8 April, Merck & Co. Inc. (NYSE:MRK) has signed a deal with private US biotech Arvinas buying into technology that could churn out new drug targets not attainable through more traditional techniques.

Leave a Reply

Your email address will not be published. Required fields are marked *